Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

Hanall News

한올소식 목록
NO 제목 작성일 작성자 조회
33 HanAll Biopharma/Daewoong Announces Topline Results for HL036 Phase 3 (VELOS-2) Study at a Press Conference 2020-01-28 admin 1663
32 HanAll Biopharma Begins Phase III Clinical Trial of HL036 in Patients with Dry Eye Disease 2019-03-12 admin 2360
31 HanAll Biopharma Announces the Results of HL036’s Phase 2 Clinical Trial at the Ophthalmology Innovation Summit (OIS) in the U.S. 2018-10-29 admin 2140
30 HanAll’s HL036 eye drops for dry eye syndrome treatment was approved of phase 2 clinical trial IND in China 2018-10-01 admin 2190
29 HanAll Biopharma Announced 1H Results of Sales increased by 12.3% YoY · It Experienced the Turnaround with Operating Profit of KRW 1.9 billion 2018-08-14 admin 1840
28 HanAll Biopharma’s New Antibody Drug, “HL161,” Accelerates its Global Development Through the Launch of Immunovant 2018-07-11 admin 2665
27 HanAll Biopharma’s HL036 was Approved of its International Nonproprietary Name (INN) by the World Health Organization (WHO) 2018-06-25 admin 2199
26 HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036 (a new drug for dry eye syndrome) in the U.S. 2018-05-29 admin 2042
25 IM156, a new drug with original technology of HanAll Biopharma, is to be Introduced at the American Society of Clinical Oncology 2018-05-24 admin 1894
24 Park Seung-kook, CEO of HanAll Biopharma Awarded of the President’s Citation on the Science Day 2018-04-23 admin 1816
현재 페이지1 2 3 4